Effect on human platelet aggregation of phospholipase A2 purified from Heloderma horridum (beaded lizard) venom.
By means of gel filtration, ionic exchange chromatography and DEAE-column HPLC, an acidic phospholipase A2 (PLA2) was purified from beaded lizard (Heloderma horridum) venom. The purified PLA is a single-chain polypeptide, consisting of about 163 amino acid residues with a molecular mass of 19,000 Da as calculated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and amino acid analysis. HHV-PLA showed a rather specific inhibitory effect on platelet aggregation induced by U46619 and epinephrine in human platelet-rich plasma in a dose- and time-dependent manner, whereas it had little effect on collagen- and ADP-induced aggregation. ATP-release reaction induced by various agonists were dose- and time-dependently inhibited by HHV-PLA, even though platelet aggregation was apparently not affected in human washed platelets. When HHV-PLA was chemically modified with p-bromophenacyl bromide, both of its enzymatic activity and antiplatelet activity were lost. Furthermore, exogenous lysophosphatidylcholine and HHV-PLA treated phosphatidylcholine inhibited platelet aggregation induced by U46619 in human washed platelets. In conclusion, PLA enzyme from H. horridum venom inhibits exclusively U46619- or thromboxane-induced platelet aggregation of human platelet-rich plasma probably by virtue of their PLA enzymatic activity on plasma phospholipids, converting phospholipids (e.g., phosphatidylcholine) into lysophospholipids, which in turn interfere with the coupling of TXA2 receptor and its signalling transduction system.
Huang
T F
TF
Pharmacological Institute, College of Medicine, National Taiwan University, Taipei.
Chiang
H S
HS
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000098:Acetophenones / Q000494:pharmacology; D000596:Amino Acids / Q000032:analysis; D000818:Animals; D004837:Epinephrine / Q000037:antagonists & inhibitors; D006801:Humans; D008116:Lizards; D008244:Lysophosphatidylcholines / Q000494:pharmacology; D008970:Molecular Weight; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000302:isolation & purification*; D054467:Phospholipases A2; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000302:isolation & purification*; D011450:Prostaglandin Endoperoxides, Synthetic / Q000037:antagonists & inhibitors; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D014688:Venoms / Q000201:enzymology*
D000098:Acetophenones; D000596:Amino Acids; D008244:Lysophosphatidylcholines; D010975:Platelet Aggregation Inhibitors; D011450:Prostaglandin Endoperoxides, Synthetic; D014688:Venoms; D013928:Thromboxane A2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D010741:Phospholipases A; D054467:Phospholipases A2; C006821:4-bromophenacyl bromide; D004837:Epinephrine